ly3857210
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 30, 2020 (NCT05986292)
Timeline
Indications
Mechanism of action
- P2X purinoceptor 7INHIBITOR
P2RX7 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05630196 | Phase 2 | Dec 8, 2022 | Eli Lilly |
| NCT05292040 | Phase 1 | Mar 17, 2022 | Eli Lilly |
| NCT05986292 | Phase 2 | Jan 30, 2020 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 2 | 2020 |
1 organizations
Page 1 / 1